L. Kutrzeba first-line liver inflammatory protection

  • 291 views
Uploaded on

 

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
291
On Slideshare
0
From Embeds
0
Number of Embeds
1

Actions

Shares
Downloads
2
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. HEPENDO First - line liver in flammatory protection LifeScience Open Space Session Kraków 2011 MEDICAL DIAGNOSTIC & MEDICAL BIOTECHNOLOGY LifeScience Open Space Session Kraków 2011
  • 2. Hependo Sp. z o.o.
    • Hependo Company was established in 2011
    • Continuation of the Trigendo company (est. 2007) – one of the first tech. transfers from academia to business
    • Shareholders of Trigendo are now participants of Hependo
    • All of the Trigendo assets have been transferred into Hependo:
      • Patent (US) and patent applications, know how of the use of the API in:
        • Drug development
        • Dietary supplements
        • Cosmetics
    LifeScience Open Space Session Kraków 2011 MEDICAL DIAGNOSTIC & MEDICAL BIOTECHNOLOGY LifeScience Open Space Session Kraków 2011
  • 3. Focus
    • Liver inflamatory caused primarily by hepatatis C virus (HCV)
    • Unmet medical need – poor sucess with current treatmnt
      • INF- α
      • Ribavirin
    • Market size:
      • 2009 – $4.4 B
      • 2016 – $8.5 B (Estimated)
    Exposed to HCV 60% Full recovery Chronic carriers 20% Cirrhosis 20% Carcinoma LifeScience Open Space Session Kraków 2011 MEDICAL DIAGNOSTIC & MEDICAL BIOTECHNOLOGY LifeScience Open Space Session Kraków 2011
  • 4. Business model Applied research Academic stage Commercial stage Tech. Transfer Capital VDDC CRO – certified results IP Out-licensing or buyout Big Pharma companies involved after PII CT LifeScience Open Space Session Kraków 2011 MEDICAL DIAGNOSTIC & MEDICAL BIOTECHNOLOGY LifeScience Open Space Session Kraków 2011
  • 5. Current status Literature search and basic research Efficacy and tox study Method of synthesis Extraction of pyr idine compounds from coffee Beginning of patent procedures Bridge financing through JCI Venture The US Patent granted for 17 therapeutic areas Alowence of continuation in USPTO for the prevention of liver related infl. Intention to grand the European patent Non-GLP supplementary experiments 2007 X 2011 Establishing Trigendo Sp. z o.o. Establishing Hependo Sp. z o.o. IV 2011 LifeScience Open Space Session Kraków 2011 MEDICAL DIAGNOSTIC & MEDICAL BIOTECHNOLOGY LifeScience Open Space Session Kraków 2011 Pre-clinical research
  • 6. Development plan Preclinical stage IND Clinical reasearch DMPK DMS TOX GEN TOX P I P II A Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 GEN TOX SING DOSE TOX REPT DOSE TOX Drug substance Drug product Stability testing LifeScience Open Space Session Kraków 2011 MEDICAL DIAGNOSTIC & MEDICAL BIOTECHNOLOGY LifeScience Open Space Session Kraków 2011
  • 7. Financing
    • Currently Hependo closes up Stage I of financing: 200 000 €
      • Preclinical (nonGLP)supplementary data
    • Stage II bugdet (expected): 4 M €
      • GLP tox and CMC
      • Filing IND application
      • Accomplishment of PI CT
    • Stage III budget (expected): 10-15 M €
      • PII A CT
    LifeScience Open Space Session Kraków 2011 MEDICAL DIAGNOSTIC & MEDICAL BIOTECHNOLOGY LifeScience Open Space Session Kraków 2011
  • 8. Thank you
    • Łukasz Kutrzeba
    • [email_address]
    • +48 515 075 500
    LifeScience Open Space Session Kraków 2011 MEDICAL DIAGNOSTIC & MEDICAL BIOTECHNOLOGY LifeScience Open Space Session Kraków 2011